SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Jibacoa who wrote (3630)4/28/2001 10:52:02 AM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
Bernard,

I've owned ELN for ages, and I don't currently own any of the major pharmas. ELN has always been attacked by the shorts (one referred to it as his "permanent short"), mostly unjustly. One issue they had was the amount of "off-books" R&D expenses, but these are clearly now reducing rapidly as a percentage of earnings.

The stock is cheap compared to the majors. The AD vaccine is a potential blockbuster (but still very speculative of course).

Peter